Daiichi Sankyo, Inc. (Daiichi)

Oncology Corporate Profile

HQ Location

Two Hilton Court
Parsippany, NJ 7054

Company Description

The Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical products to address the diversified, unmet medical needs of patients in both mature and emerging markets. While maintaining its portfolio of marketed pharmaceuticals for hypertension, hyperlipidemia, and bacterial infections, the Group is engaged in the development of treatments for thrombotic disorders and focused on the discovery of novel oncology and cardiovascular-metabolic therapies.

Website: http://dsi.com/

Brand Generic Indication
Zelboraf®vemurafenibZelboraf® is a kinase inhibitor indicated for the treatment of patients with unresectable or metastatic melanoma with BRAFV600E mutation as detected by an FDA-approved test. Zelboraf® is not recommended for use in patients with wild-type BRAF melanoma.

View additional information on commercial products here »

  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
quizartinibFLT3-ITD inhibitorAcute Myelogenous Leukemia (AML)III
denosumabanti-RANKL antibodyBreast cancerIII
nimotuzumabanti-EGFR antibodyGastric cancerIII
tivantinibMET inhibitorHepatocellular carcinoma (HCC)III
vemurafenibBRAF inhibitorMelanomaIII
pexidartinibCSF-1R/KIT/FLT3-ITD inhibitorTenosynovial Giant Cell Tumor (TGCT)III
pexidartinib / PLX3397CSF-1R/KIT/FLT3-ITD inhibitorGlioblastomaII
DS-1647oncolytic HSV-1GlioblastomaII
pexidartinib (+ pembrolizumab) / PLX3397CSF-1R/KIT/FLT3-ITD inhibitorMelanomaIIMerck
DS-3032MDM2 inhibitorLeukemiaI
DS-3032MDM2 inhibitorLymphomaI
DS-3201EZH1/2 inhibitorNon-Hodgkin's Lymphoma (NHL)I
PLX73086CSF1R inhibitorTenosynovial Giant Cell Tumor (TGCT)I
PLX8394BRAF inhibitorVarious cancer typesI
PLX7486FMS/TRK inhibitorVarious cancer typesI
PLX9486KIT inhibitorVarious cancer typesI
DS-6051NTRK/ROS1 inhibitorVarious cancer typesI
PLX51107BRD4 inhibitorVarious cancer typesI
DS-8895anti-EPHA2 antibodyVarious cancer typesI
DS-8201anti-HER2 antibody drug conjugateVarious cancer typesI
DS-5573anti-B7-H3 antibodyVarious cancer typesI
DS-8273anti-DR5 antibodyVarious cancer typesI
U3-1402anti-HER3 antibody drug conjugateVarious cancer typesI
DS-1123anti-FGFR4 antibodyVarious cancer typesI
U3-1784anti-FGFR4 antibodyVarious cancer typesI

View additional information on product candidates here »

Source: http://dsi.com/

Recent News Headlines

There are no news items to display